Drug-related problems and hospital admissions in cardiac transplant recipients;Problèmes liés aux médicaments et hospitalisations chez les patients greffés cardiaques

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1299-1307

  Repp, Kristin L ^a   Hayes III, Charles ^b   Mark Woods, T ^b   Allen, Keith B ^c   Kennedy, Kevin ^c   Borkon, Michael A ^c  

^a Saint Luke's North Hospital   (United States)

^b Saint Luke's Hospital of Kansas City   (United States)

^c Saint Luke's Hos pital of Kansas City ^*  (United States)

Author keywords

Adverse reaction; Preventability; Transplant

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ATOVAQUONE; CALCIUM; ELECTROLYTE; FUROSEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIVITAMIN; MYCOPHENOLIC ACID; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; TACROLIMUS; VITAMIN D;

ADULT; ARTICLE; ASPIRATION PNEUMONIA; CAUSE OF DEATH; CLINICAL ARTICLE; CONVALESCENCE; DEHYDRATION; DISABILITY; DRUG INDUCED DISEASE; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HUMAN; INCIDENCE; LENGTH OF STAY; LONGITUDINAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SUPRAVENTRICULAR TACHYCARDIA; URINARY TRACT INFECTION;

ADULT; AGED; DRUG TOXICITY; FEMALE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS;

EID: 84867790791     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R094     Document Type: Article

References (30)

1. Beijer HJM, deBlaey CJ. Hospitalisations caused by adverse drug reac-tions (ADR): a meta-analysis of observational studies. Pharm World Sci 2002;24:46-54. doi: 10.1023/A:1015570104121
2. Brvar M, Fokter N, Bunc M, Mozina M. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharm 2009;9:8. doi: 10.1186/1472-6904-9-8
3. Leendertse AJ, Egberts ACG, Stoker LJ, et al., for the HARM study group. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008;168: 1890-6.
4. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004;329:15-9. doi: 10.1136/bmj.329.7456.15
5. Samoy LJ, Zed PJ, Wilbur K, et al. Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study. Pharmacotherapy 2006;26:1578-86. doi: 10.1592/phco.26.11.1578
6. Committee on Quality of Health Care in America, Institute of Medicine. Executive summary. In: To err is human. Washington, DC: National Academy Press, 2000:1-17.
7. Ernst FR, Grizzle AJ. Drug related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash) 2001;41:192-9.
8. Olivier P, Olivier B, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice. Drug Safety 2002;25:1035-44.
9. McDonnell PJ, Jacobs MR. Hospital admissions resulting from pre-ventable adverse drug reactions. Ann Pharmacother 2002;36:1331-6. doi: 10.1345/aph.1A333
10. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66. doi: 10.1001/jama.296.15.1858
11. Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Direct patient care services provided by a pharmacist on a multidisciplinary renal transplant team. Am J Health Syst Pharm 2000;57:1599-601.
12. Wang HY, Chan ALF, Chen MT, et al. Effects of pharmaceutical care in-tervention by clinical pharmacists in renal transplant clinics. Transplant Proc 2008;40:2319-23. doi: 10.1016/j.transproceed.2008.06.050
13. Prot-Labarthe S, Therrien R, Demanche C, et al. Pharmaceutical care in an inpatient pediatric hematopoietic stem cell transplant service. J Oncol Pharm Pract 2008;14:147-52. doi: 10.1177/1078155208093929
14. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Prac-tice Study I. N Engl J Med 1991;324:370-7. doi: 10.1056/NEJM199102073240604
15. Baker GR, Norton PG, Flintoft V, et al. The Canadian Adverse Event study: the incidence of adverse events among hospital patients in Cana-da. CMAJ 2004;170:1678-86. doi: 10.1503/cmaj.1040498
16. Forster AJ, Asmis TR, Clark HD, et al. Ottawa hospital patient safety study: incidence and timing of adverse events in patients admitted to a Canadian teach hospital. CMAJ 2004;170:1235-40. doi: 10.1503/cmaj.1030683
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the proba-bility of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. doi: 10.1038/clpt.1981.154
18. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceu-tical care. Am J Hosp Pharm 1990;47:533-43.
19. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater relia-bility. Psychological Bull 1979;86:420-8.
20. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart trans-plant recipient. Part I: cardiac rejection and immunosuppressive drugs. Cir-culation 2004;110:3734-40. doi: 10.1161/01.CIR.0000149745.83186.89
21. Lindenfield J, Page RL, Zolty R, et al. Drug therapy in the heart trans-plant recipient. Part III: common medical problems. Circulation 2005;111:113-7. doi: 10.1161/01.CIR.0000151609.60618.3C
22. Kaboli PJ, Glasgow JM, Jaipaul CK, et al. Identifying medication misad-ventures: poor agreement among medical record physician, nurse, and patient reports. Pharmacotherapy 2010;30:529-38. doi: 10.1592/phco.30.5.529
23. Committee on Identifying and Preventing Medication Errors. Action Agenda for Health Care Organizations. In: Preventing medication errors: quality chasm series. 1st ed. Washington, DC: National Academies Press, 2006:221-65.
24. Cabezas CL, Salvador CF, Quadrada DC, et al. Randomized clinical trial of a post discharge pharmaceutical care program vs. regular follow-up in patients with heart failure. Farm Hosp 2006;30:328-42.
25. Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure. Ann Intern Med 2007;146:714-25.
26. Roughead EE, Barratt JD, Ramsay E, et al. The effectiveness of collabo-rative medicine reviews in delaying time to next hospitalization for heart failure patients in the practice setting. Circ Heart Failure 2009;2:424-8. doi: 10.1161/CIRCHEARTFAILURE.109.861013
27. Torner MQG, Planas ACG, Zubia IA, et al. The participation of the phar-macist in the design and follow-up of the drug treatment plan for patients with cardiovascular condition. Farm Hosp 2008;32:148-56.
28. Triller DM, Hamilton RA. Effect of pharmaceutical care services on out-comes for home care patients with heart failure. Am J Health Syst Pharm 2007;64:2244-9. doi: 10.2146/ajhp050492
29. United Network of Organ Sharing. Designated transplant program crite-ria. Bylaws attachment I to Appendix B:92-93. http://www.unos.org/docs/Appendix_B_AttachI_XIII.pdf (accessed 2012 Apr 23).
30. Federal Register. Department of Health and Human Services. Part II. March 2007; 72:15205-15237. http://www.gpo.gov/fdsys/pkg/FR-2007-03-30/pdf/07-1435.pdf